Transient Ischaemic Attack (TIA) Prediction Rules

Total Page:16

File Type:pdf, Size:1020Kb

Transient Ischaemic Attack (TIA) Prediction Rules National Institute for Health and Care Excellence 1 Draft for consultation Stroke (update) Evidence review B: transient ischaemic attack (TIA) prediction rules NICE guideline Prognostic evidence review November 2018 Draft for consultation This evidence review was developed by the National Guideline Centre STROKE (UPDATE): DRAFT FOR CONSULTATION Contents 1 Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian. Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn. Copyright © NICE 2018. All rights reserved. Subject to Notice of rights. STROKE (UPDATE): DRAFT FOR CONSULTATION Contents Contents 1 Risk prediction scores ................................................................................................. 5 1.1 Review question: How accurately do scoring systems predict the risks of future ischaemic stroke or transient ischaemic attack (TIA) within the first 7 days in people with suspected TIA? ...................................................................... 5 1.2 Introduction ........................................................................................................... 5 1.3 PICO table ............................................................................................................. 5 1.4 Methods and process ............................................................................................ 6 1.5 Clinical evidence ................................................................................................... 6 1.5.1 Included studies ......................................................................................... 6 1.5.2 Excluded studies ........................................................................................ 8 1.5.4 Quality assessment of clinical studies included in the evidence review .... 11 1.6 Economic evidence ............................................................................................. 15 1.6.1 Included studies ....................................................................................... 15 1.6.2 Summary of studies included in the economic evidence review ............... 16 1.6.3 Unit costs ................................................................................................. 19 1.7 Resource costs ................................................................................................... 19 1.8 Evidence statements ........................................................................................... 19 1.8.1 Clinical evidence statements .................................................................... 19 1.8.2 Health economic evidence statements ..................................................... 20 1.9 Recommendations .............................................................................................. 20 B2. Do not use scoring systems, such as ABCD2, to assess risk of subsequent stroke. [2019] ........................................................................ 20 1.10 Rationale and impact ........................................................................................... 20 1.10.1 Why the committee made the recommendations ...................................... 20 1.10.2 Impact of the recommendations on practice ............................................. 21 1.11 The committee’s discussion of the evidence ........................................................ 22 1.11.1 Interpreting the evidence .......................................................................... 22 1.11.2 Cost effectiveness and resource use ....................................................... 23 1.11.3 Other factors the committee took into account ......................................... 24 Appendices ........................................................................................................................ 33 Appendix A: Review protocols ................................................................................... 33 Appendix B: Literature search strategies ................................................................... 38 B.1 Clinical search literature search strategy ...................................................... 38 B.2 Health Economics literature search strategy ................................................. 43 B.2.1 Health economics search ................................................................ 43 Appendix C: Clinical evidence selection ..................................................................... 48 Appendix D: Clinical evidence tables ......................................................................... 49 Appendix E: Health economic evidence selection ...................................................... 62 Appendix F: Health economic evidence tables .......................................................... 64 3 STROKE (UPDATE): DRAFT FOR CONSULTATION Contents Appendix G: Excluded studies.................................................................................... 67 G.1 Excluded clinical studies ............................................................................... 67 1 4 STROKE (UPDATE): DRAFT FOR CONSULTATION Risk prediction scores 1 1 Risk prediction scores 1.1 2 Review question: How accurately do scoring systems 3 predict the risks of future ischaemic stroke or transient 4 ischaemic attack (TIA) within the first 7 days in people with 5 suspected TIA? 1.2 6 Introduction 7 Patients who have experienced a TIA are at increased risk of having a stroke in the days and 8 weeks following the TIA. Scoring systems have been developed to stratify TIA patients 9 according to their individual future risk of stroke or TIA. The results of these TIA risk scoring 10 systems have been used to guide decisions about the rapidity of access to specialist 11 assessment following a TIA; however these tools are not applied consistently in practice. The 12 committee considered how accurately these scoring systems predicted the risk of stroke or 13 TIA in the first seven days following a TIA and whether these should be used to guide current 14 practice. 1.3 15 PICO table 16 For full details see the review protocol in appendix A. 17 Table 1: PICO characteristics of review question Population People aged over 16 with suspected TIA Risk tool Validated risk stratification tools/scoring systems (ABCD2 and other variants e.g. ABCD2-I, ABCD3, ABCD3-I) Target Stroke or TIA within 7 days condition Outcomes Discrimination (area under curve [c statistic]) Calibration (R2, Brier Score, Hosmer-Lemeshow test statistic; Somers’ D statistic), Calibration plot Reclassification These will be assessed for the following outcomes: Critical Risk of stroke (stroke at 24 hours, 72 hours and 7 days) Mortality (7 day) Important Functional outcomes – modified Rankin scale (mRS) 90 days and 1 year Quality of life Study design Prospective observational studies Systematic reviews and meta-analyses of the above Exclusions: derivation studies/internal validation studies © NICE 2018. All rights reserved. Subject to Notice of rights. 5 STROKE (UPDATE): DRAFT FOR CONSULTATION Risk prediction scores 1.4 1 Methods and process 2 This evidence review was developed using the methods and process described in 3 Developing NICE guidelines: the manual.19 Methods specific to this review question are 4 described in the review protocol in appendix A. 5 Declarations of interest were recorded according to NICE’s 2014 conflicts of interest policy 6 upto March 2018, and NICE’s 2018 conflicts of interest policy from April 2018. 7 Risk of bias was assessed using the prediction study risk of bias assessment tool 8 (PROBAST) risk of bias checklist for primary studies or the ROBIS checklist for systematic 9 reviews, including individual patient data (IPD) meta-analyses. IPD analyses were included in 10 the same way as published systematic reviews, with the outcomes reported as described in 11 the IPD analysis and risk of bias assessed for the IPD analysis per outcome. 12 Note that this question is an update and included in the previous guideline. Search strategies 13 run from 2008 onward. The previous guideline included 4 studies,10, 42, 74, 82 none of which 14 meet the protocol for this review. Three of these studies related
Recommended publications
  • ABCG1 (ABC8), the Human Homolog of the Drosophila White Gene, Is a Regulator of Macrophage Cholesterol and Phospholipid Transport
    ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport Jochen Klucken*, Christa Bu¨ chler*, Evelyn Orso´ *, Wolfgang E. Kaminski*, Mustafa Porsch-Ozcu¨ ¨ ru¨ mez*, Gerhard Liebisch*, Michael Kapinsky*, Wendy Diederich*, Wolfgang Drobnik*, Michael Dean†, Rando Allikmets‡, and Gerd Schmitz*§ *Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, 93042 Regensburg, Germany; †National Cancer Institute, Laboratory of Genomic Diversity, Frederick, MD 21702-1201; and ‡Departments of Ophthalmology and Pathology, Columbia University, Eye Research Addition, New York, NY 10032 Edited by Jan L. Breslow, The Rockefeller University, New York, NY, and approved November 3, 1999 (received for review June 14, 1999) Excessive uptake of atherogenic lipoproteins such as modified low- lesterol transport. Although several effector molecules have been density lipoprotein complexes by vascular macrophages leads to proposed to participate in macrophage cholesterol efflux (6, 9), foam cell formation, a critical step in atherogenesis. Cholesterol efflux including endogenous apolipoprotein E (10) and the cholesteryl mediated by high-density lipoproteins (HDL) constitutes a protective ester transfer protein (11), the detailed molecular mechanisms mechanism against macrophage lipid overloading. The molecular underlying cholesterol export in these cells have not yet been mechanisms underlying this reverse cholesterol transport process are characterized. currently not fully understood. To identify effector proteins that are Recently, mutations of the ATP-binding cassette (ABC) trans- involved in macrophage lipid uptake and release, we searched for porter ABCA1 gene have been causatively linked to familial HDL genes that are regulated during lipid influx and efflux in human deficiency and Tangier disease (12–14).
    [Show full text]
  • Genome-Wide Identification of Whole ATP-Binding Cassette (ABC)
    Jeong et al. BMC Genomics 2014, 15:651 http://www.biomedcentral.com/1471-2164/15/651 RESEARCH ARTICLE Open Access Genome-wide identification of whole ATP-binding cassette (ABC) transporters in the intertidal copepod Tigriopus japonicus Chang-Bum Jeong1, Bo-Mi Kim2, Jae-Seong Lee2* and Jae-Sung Rhee3* Abstract Backgrounds: The ATP-binding cassette (ABC) transporter superfamily is one of the largest transporter gene families and is observed in all animal taxa. Although a large set of transcriptomic data was recently assembled for several species of crustaceans, identification and annotation of the large ABC transporter gene family have been very challenging. Results: In the intertidal copepod Tigriopus japonicus, 46 putative ABC transporters were identified using in silico analysis, and their full-length cDNA sequences were characterized. Phylogenetic analysis revealed that the 46 T. japonicus ABC transporters are classified into eight subfamilies (A-H) that include all the members of all ABC subfamilies, consisting of five ABCA, five ABCB, 17 ABCC, three ABCD, one ABCE, three ABCF, seven ABCG, and five ABCH subfamilies. Of them, unique isotypic expansion of two clades of ABCC1 proteins was observed. Real-time RT-PCR-based heatmap analysis revealed that most T. japonicus ABC genes showed temporal transcriptional expression during copepod development. The overall transcriptional profile demonstrated that half of all T. japonicus ABC genes were strongly associated with at least one developmental stage. Of them, transcripts TJ-ABCH_88708 and TJ-ABCE1 were highly expressed during all developmental stages. Conclusions: The whole set of T. japonicus ABC genes and their phylogenetic relationships will provide a better understanding of the comparative evolution of essential gene family resources in arthropods, including the crustacean copepods.
    [Show full text]
  • Transcriptional and Post-Transcriptional Regulation of ATP-Binding Cassette Transporter Expression
    Transcriptional and Post-transcriptional Regulation of ATP-binding Cassette Transporter Expression by Aparna Chhibber DISSERTATION Submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmaceutical Sciences and Pbarmacogenomies in the Copyright 2014 by Aparna Chhibber ii Acknowledgements First and foremost, I would like to thank my advisor, Dr. Deanna Kroetz. More than just a research advisor, Deanna has clearly made it a priority to guide her students to become better scientists, and I am grateful for the countless hours she has spent editing papers, developing presentations, discussing research, and so much more. I would not have made it this far without her support and guidance. My thesis committee has provided valuable advice through the years. Dr. Nadav Ahituv in particular has been a source of support from my first year in the graduate program as my academic advisor, qualifying exam committee chair, and finally thesis committee member. Dr. Kathy Giacomini graciously stepped in as a member of my thesis committee in my 3rd year, and Dr. Steven Brenner provided valuable input as thesis committee member in my 2nd year. My labmates over the past five years have been incredible colleagues and friends. Dr. Svetlana Markova first welcomed me into the lab and taught me numerous laboratory techniques, and has always been willing to act as a sounding board. Michael Martin has been my partner-in-crime in the lab from the beginning, and has made my days in lab fly by. Dr. Yingmei Lui has made the lab run smoothly, and has always been willing to jump in to help me at a moment’s notice.
    [Show full text]
  • ABC Transporter Subfamily D: Distinct Differences in Behavior Between ABCD1–3 and ABCD4 in Subcellular Localization, Function, and Human Disease
    Hindawi Publishing Corporation BioMed Research International Volume 2016, Article ID 6786245, 11 pages http://dx.doi.org/10.1155/2016/6786245 Review Article ABC Transporter Subfamily D: Distinct Differences in Behavior between ABCD1–3 and ABCD4 in Subcellular Localization, Function, and Human Disease Kosuke Kawaguchi and Masashi Morita Department of Biological Chemistry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan Correspondence should be addressed to Kosuke Kawaguchi; [email protected] Received 24 June 2016; Accepted 29 August 2016 Academic Editor: Hiroshi Nakagawa Copyright © 2016 K. Kawaguchi and M. Morita. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ATP-binding cassette (ABC) transporters are one of the largest families of membrane-bound proteins and transport a wide variety of substrates across both extra- and intracellular membranes. They play a critical role in maintaining cellular homeostasis. To date, four ABC transporters belonging to subfamily D have been identified. ABCD1–3 and ABCD4 are localized to peroxisomes and lysosomes, respectively. ABCD1 and ABCD2 are involved in the transport of long and very long chain fatty acids (VLCFA) or their CoA-derivatives into peroxisomes with different substrate specificities, while ABCD3 is involved in the transport of branched chain acyl-CoA into peroxisomes. On the other hand, ABCD4 is deduced to take part in the transport of vitamin B12 from lysosomes into the cytosol. It is well known that the dysfunction of ABCD1 results in X-linked adrenoleukodystrophy, a severe neurodegenerative disease.
    [Show full text]
  • ABCD2 Is a Direct Target of B-Catenin and TCF-4: Implications for X-Linked Adrenoleukodystrophy Therapy
    ABCD2 Is a Direct Target of b-Catenin and TCF-4: Implications for X-Linked Adrenoleukodystrophy Therapy Chul-Yong Park1,2, Han-Soo Kim3, Jiho Jang1,2, Hyunji Lee1,2, Jae Souk Lee1,2,4, Jeong-Eun Yoo1,2,4, Dongjin R. Lee1,2,4, Dong-Wook Kim1,2,4* 1 Department of Physiology, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea, 2 Severance Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Korea, 3 Department of Laboratory Medicine and Cell Therapy Center, Yonsei University College of Medicine, Seoul, Korea, 4 Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea Abstract X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder caused by mutations in the ABCD1 gene that encodes the peroxisomal ATP-binding cassette (ABC) transporter subfamily D member 1 protein (ABCD1), which is referred to as the adrenoleukodystrophy protein (ALDP). Induction of the ABCD2 gene, the closest homolog of ABCD1, has been mentioned as a possible therapeutic option for the defective ABCD1 protein in X-ALD. However, little is known about the transcriptional regulation of ABCD2 gene expression. Here, through in silico analysis, we found two putative TCF-4 binding elements between nucleotide positions 2360 and 2260 of the promoter region of the ABCD2 gene. The transcriptional activity of the ABCD2 promoter was strongly increased by ectopic expression of b-catenin and TCF-4. In addition, mutation of either or both TCF-4 binding elements by site-directed mutagenesis decreased promoter activity. This was further validated by the finding that b-catenin and the promoter of the ABCD2 gene were pulled down with a b-catenin antibody in a chromatin immunoprecipitation assay.
    [Show full text]
  • Whole Exome Sequencing Analysis of ABCC8 and ABCD2 Genes Associating with Clinical Course of Breast Carcinoma
    Physiol. Res. 64 (Suppl. 4): S549-S557, 2015 Whole Exome Sequencing Analysis of ABCC8 and ABCD2 Genes Associating With Clinical Course of Breast Carcinoma P. SOUCEK1,2, V. HLAVAC1,2,3, K. ELSNEROVA1,2,3, R. VACLAVIKOVA2, R. KOZEVNIKOVOVA4, K. RAUS5 1Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic, 2Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic, 3Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 4Department of Oncosurgery, Medicon, Prague, Czech Republic, 5Institute for the Care for Mother and Child, Prague, Czech Republic Received September 17, 2015 Accepted October 2, 2015 Summary Charles University in Prague, Alej Svobody 76, 323 00 Pilsen, The aim of the present study was to introduce methods for Czech Republic. E-mail: [email protected] exome sequencing of two ATP-binding cassette (ABC) transporters ABCC8 and ABCD2 recently suggested to play Introduction a putative role in breast cancer progression and prognosis of patients. We performed next generation sequencing targeted at Breast cancer is the most common cancer in analysis of all exons in ABCC8 and ABCD2 genes and surrounding women and caused 471,000 deaths worldwide in 2013 noncoding sequences in blood DNA samples from 24 patients (Global Burden of Disease Cancer Collaboration 2015). with breast cancer. The revealed alterations were characterized A number of cellular processes that in some cases lead to the by in silico tools. We then compared the most frequent tumor resistance limits efficacy of breast cancer therapy. functionally relevant polymorphism rs757110 in ABCC8 with Multidrug resistance (MDR) to a variety of chemotherapy clinical data of patients.
    [Show full text]
  • Whole Exome Sequencing Analysis of ABCC8 and ABCD2 Genes Associating with Clinical Course of Breast Carcinoma
    Physiol. Res. 64 (Suppl. 4): S549-S557, 2015 https://doi.org/10.33549/physiolres.933212 Whole Exome Sequencing Analysis of ABCC8 and ABCD2 Genes Associating With Clinical Course of Breast Carcinoma P. SOUCEK1,2, V. HLAVAC1,2,3, K. ELSNEROVA1,2,3, R. VACLAVIKOVA2, R. KOZEVNIKOVOVA4, K. RAUS5 1Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic, 2Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic, 3Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 4Department of Oncosurgery, Medicon, Prague, Czech Republic, 5Institute for the Care for Mother and Child, Prague, Czech Republic Received September 17, 2015 Accepted October 2, 2015 Summary Charles University in Prague, Alej Svobody 76, 323 00 Pilsen, The aim of the present study was to introduce methods for Czech Republic. E-mail: [email protected] exome sequencing of two ATP-binding cassette (ABC) transporters ABCC8 and ABCD2 recently suggested to play Introduction a putative role in breast cancer progression and prognosis of patients. We performed next generation sequencing targeted at Breast cancer is the most common cancer in analysis of all exons in ABCC8 and ABCD2 genes and surrounding women and caused 471,000 deaths worldwide in 2013 noncoding sequences in blood DNA samples from 24 patients (Global Burden of Disease Cancer Collaboration 2015). with breast cancer. The revealed alterations were characterized A number of cellular processes that in some cases lead to the by in silico tools. We then compared the most frequent tumor resistance limits efficacy of breast cancer therapy. functionally relevant polymorphism rs757110 in ABCC8 with Multidrug resistance (MDR) to a variety of chemotherapy clinical data of patients.
    [Show full text]
  • Identification of Novel Snps of ABCD1, ABCD2, ABCD3
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Neurogenetics (2011) 12:41–50 DOI 10.1007/s10048-010-0253-6 ORIGINAL ARTICLE Identification of novel SNPs of ABCD1, ABCD2, ABCD3, and ABCD4 genes in patients with X-linked adrenoleukodystrophy (ALD) based on comprehensive resequencing and association studies with ALD phenotypes Takashi Matsukawa & Muriel Asheuer & Yuji Takahashi & Jun Goto & Yasuyuki Suzuki & Nobuyuki Shimozawa & Hiroki Takano & Osamu Onodera & Masatoyo Nishizawa & Patrick Aubourg & Shoji Tsuji Received: 15 May 2010 /Accepted: 9 July 2010 /Published online: 27 July 2010 # The Author(s) 2010. This article is published with open access at Springerlink.com Abstract Adrenoleukodystrophy (ALD) is an X-linked dis- French ALD cohort with extreme phenotypes. All the order affecting primarily the white matter of the central mutations of ABCD1 were identified, and there was no nervous system occasionally accompanied by adrenal insuffi- correlation between the genotypes and phenotypes of ALD. ciency. Despite the discovery of the causative gene, ABCD1, SNPs identified by the comprehensive resequencing of no clear genotype–phenotype correlations have been estab- ABCD2, ABCD3,andABCD4 were used for association lished. Association studies based on single nucleotide poly- studies. There were no significant associations between these morphisms (SNPs) identified by comprehensive resequencing SNPs and ALD phenotypes, except for the five SNPs of of genes related to ABCD1 may reveal genes modifying ALD ABCD4, which are in complete disequilibrium in the phenotypes. We analyzed 40 Japanese patients with ALD. Japanese population. These five SNPs were significantly less ABCD1 and ABCD2 were analyzed using a newly developed frequently represented in patients with adrenomyeloneurop- microarray-based resequencing system.
    [Show full text]
  • Prediction of Recurrent Stroke with ABCD2 and ABCD3 Scores in Patients with Symptomatic 50-99% Carotid Stenosis Elias Johansson1,2*, Jakob Bjellerup2 and Per Wester2
    Johansson et al. BMC Neurology 2014, 14:223 http://www.biomedcentral.com/1471-2377/14/223 RESEARCH ARTICLE Open Access Prediction of recurrent stroke with ABCD2 and ABCD3 scores in patients with symptomatic 50-99% carotid stenosis Elias Johansson1,2*, Jakob Bjellerup2 and Per Wester2 Abstract Background: Although it is preferable that all patients with a recent Transient Ischemic Attack (TIA) undergo acute carotid imaging, there are centers with limited access to such acute examinations. It is controversial whether ABCD2 or ABCD3 scores can be used to triage patients to acute or delayed carotid imaging. It would be acceptable that some patients with a symptomatic carotid stenosis are detected with a slight delay as long as those who will suffer an early recurrent stroke are detected within 24 hours. The aim of this study is to analyze the ability of ABCD2 and ABCD3 scores to predict ipsilateral ischemic stroke among patients with symptomatic 50-99% carotid stenosis. Methods: In this secondary analysis of the ANSYSCAP-study, we included 230 consecutive patients with symptomatic 50-99% carotid stenosis. We analyzed the risk of recurrent ipsilateral ischemic stroke before carotid endarterectomy based on each parameter of the ABCD2 and ABCD3 scores separately, and for total ABCD2 and ABCD3 scores. We used Kaplan-Meier analysis. Results: None of the parameters in the ABCD2 or ABCD3 scores could alone predict all 12 of the ipsilateral ischemic strokes that occurred within 2 days of the presenting event, but clinical presentation tended to be a statistically significant risk factor for recurrent ipsilateral ischemic stroke (p = 0.06, log rank test).
    [Show full text]
  • Peroxisomal ATP-Binding Cassette Transporters Form Mainly Tetramers
    Peroxisomal ATP-binding cassette transporters form mainly tetramers Flore Geillon, Catherine Gondcaille, Quentin Raas, Alexandre Dias, Delphine Pecqueur, Caroline Truntzer, Géraldine Lucchi, Patrick Ducoroy, Pierre Falson, Stéphane Savary, et al. To cite this version: Flore Geillon, Catherine Gondcaille, Quentin Raas, Alexandre Dias, Delphine Pecqueur, et al.. Per- oxisomal ATP-binding cassette transporters form mainly tetramers. Journal of Biological Chem- istry, American Society for Biochemistry and Molecular Biology, 2017, 292 (17), pp.6965-6977. 10.1074/jbc.M116.772806. hal-02329531 HAL Id: hal-02329531 https://hal.archives-ouvertes.fr/hal-02329531 Submitted on 23 Oct 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. cros ARTICLE Peroxisomal ATP-binding cassette transporters form mainly tetramers Received for publication, December 16, 2016, and in revised form, March 3, 2017 Published, Papers in Press, March 3, 2017, DOI 10.1074/jbc.M116.772806 Flore Geillon‡, Catherine Gondcaille‡, Quentin Raas‡, Alexandre M. M. Dias‡, Delphine Pecqueur§, Caroline Truntzer§, Géraldine Lucchi§, Patrick Ducoroy§, Pierre Falson¶, Stéphane Savary‡, and Doriane Trompier‡1 From the ‡Laboratoire Bio-PeroxIL EA7270 and §CLIPP-ICMUB, Universite´Bourgogne-Franche-Comté, 6 Bd Gabriel, 21000 Dijon, France and the ¶Drug Resistance and Membrane Proteins Team, Molecular Microbiology and Structural Biochemistry Laboratory, Institut de Biologie et Chimie des Protéines (IBCP), UMR5086 CNRS/Université Lyon 1, 7 Passage du Vercors, 69367 Lyon, France Edited by George M.
    [Show full text]
  • Peroxisomal Cofactor Transport
    biomolecules Review Peroxisomal Cofactor Transport Anastasija Plett, Lennart Charton and Nicole Linka * Institute of Plant Biochemistry and Cluster of Excellence on Plant Sciences (CEPLAS), Heinrich Heine University, Universitätsstrasse 1, 40,225 Düsseldorf, Germany; [email protected] (A.P.); [email protected] (L.C.) * Correspondence: [email protected]; Tel.: +49-(0)211-81-10412; Fax: +49-(0)211-81-13706 Received: 2 July 2020; Accepted: 7 August 2020; Published: 12 August 2020 Abstract: Peroxisomes are eukaryotic organelles that are essential for growth and development. They are highly metabolically active and house many biochemical reactions, including lipid metabolism and synthesis of signaling molecules. Most of these metabolic pathways are shared with other compartments, such as Endoplasmic reticulum (ER), mitochondria, and plastids. Peroxisomes, in common with all other cellular organelles are dependent on a wide range of cofactors, such as adenosine 50-triphosphate (ATP), Coenzyme A (CoA), and nicotinamide adenine dinucleotide (NAD). The availability of the peroxisomal cofactor pool controls peroxisome function. The levels of these cofactors available for peroxisomal metabolism is determined by the balance between synthesis, import, export, binding, and degradation. Since the final steps of cofactor synthesis are thought to be located in the cytosol, cofactors must be imported into peroxisomes. This review gives an overview about our current knowledge of the permeability of the peroxisomal membrane with the focus on ATP, CoA, and NAD. Several members of the mitochondrial carrier family are located in peroxisomes, catalyzing the transfer of these organic cofactors across the peroxisomal membrane. Most of the functions of these peroxisomal cofactor transporters are known from studies in yeast, humans, and plants.
    [Show full text]
  • Connecting Cholesterol Efflux Factors to Lung Cancer Biology And
    International Journal of Molecular Sciences Review Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics Maria Maslyanko †, Ryan D. Harris † and David Mu * Leroy T. Canoles Jr. Cancer Research Center, Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA 23501, USA; [email protected] (M.M.); [email protected] (R.D.H.) * Correspondence: [email protected] † Equal contribution. Abstract: Cholesterol is a foundational molecule of biology. There is a long-standing interest in understanding how cholesterol metabolism is intertwined with cancer biology. In this review, we focus on the known connections between lung cancer and molecules mediating cholesterol efflux. A major take-home lesson is that the roles of many cholesterol efflux factors remain underexplored. It is our hope that this article would motivate others to investigate how cholesterol efflux factors contribute to lung cancer biology. Keywords: lung cancer; cholesterol efflux; ABCA1; ABCG1; Apo AI; miRNA; miR-33a; miR-200b-3p; LRPs; LAL; NPC1; STARD3; SMPD1; NCEH1; SR-BI; TTF-1; drug resistance; cisplatin 1. Introduction Citation: Maslyanko, M.; Harris, Cholesterol is essential for cell viability and cell membrane integrity. Cholesterol is R.D.; Mu, D. Connecting Cholesterol also a precursor to many physiologically important hormones. The interest in the intercon- Efflux Factors to Lung Cancer Biology nection between cholesterol metabolism and cancer is best illustrated by the abundance of and Therapeutics. Int. J. Mol. Sci. literature on this subject matter. A quick search of PubMed.gov (accessed on 4 June 2021) 2021, 22, 7209. https://doi.org/ using the two key words (Cholesterol AND Cancer) retrieves over 20,000 publications.
    [Show full text]